Literature DB >> 2167685

Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate.

R I Sperling1, J S Coblyn, J K Larkin, A I Benincaso, K F Austen, M E Weinblatt.   

Abstract

We studied the effects of a single, oral dose of methotrexate (MTX) on arachidonic acid metabolism in neutrophils from 6 patients with rheumatoid arthritis, which were obtained 1 day before and 1 day after their usual weekly MTX dose. The 6 patients had received a mean weekly MTX dose of 9.6 mg (range 5-15) for a mean of 61.7 months (range 58-64), and none received concomitant corticosteroids. Total generation of leukotriene B4 (LTB4) in neutrophils stimulated ex vivo with 10 microM calcium ionophore A23187 for 20 minutes was significantly suppressed, by a mean of 53%, after the MTX dose compared with the predose levels (mean +/- SEM 13.0 +/- 1.4 ng/10(6) cells versus 6.0 +/- 0.9 ng/10(6) cells; P = 0.0019), reflecting a comparable suppression of both released and cell-retained LTB4. A 49% decrease in omega-oxidation products of LTB4 demonstrates that decreased LTB4 synthesis, rather than increased degradation, is responsible for the decrease in LTB4 generation. The absence of a significant change in either 3H-labeled arachidonic acid release or platelet-activating factor generation indicates that the observed decrease in LTB4 synthesis was apparently not caused by diminished phospholipase A2 activity. A 28% decrease in the total formation of the 5-lipoxygenase products 5-hydroxyeicosatetraenoic acid and the 6-trans-LTB4 diastereoisomers, and a 48% suppression of production of LTB4 plus its omega-oxidation metabolites after the MTX dose suggest inhibition of 5-lipoxygenase activity and possible suppression of leukotriene A4 epoxide hydrolase activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167685     DOI: 10.1002/art.1780330815

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

Review 1.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 2.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema.

Authors:  Eliseu O De Oliveira; Kan Wang; Hye-Sik Kong; Suhyon Kim; Matthew Miessau; Robert J Snelgrove; Y Michael Shim; Mikell Paige
Journal:  Bioorg Med Chem Lett       Date:  2011-09-20       Impact factor: 2.823

4.  Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis.

Authors:  K Hildner; S Finotto; C Becker; J Schlaak; P Schirmacher; P R Galle; E Märker-Hermann; M F Neurath
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

5.  Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?

Authors:  L D Fairbanks; K Rückemann; Y Qiu; C M Hawrylowicz; D F Richards; R Swaminathan; B Kirschbaum; H A Simmonds
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

Review 6.  Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.

Authors:  Jing Liu; Jie Zhao; Liang Hu; Yuchun Cao; Bo Huang
Journal:  Cell Mol Immunol       Date:  2011-03-21       Impact factor: 11.530

7.  Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis.

Authors:  E Thomas; J L Leroux; F Blotman; C Chavis
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

8.  Methotrexate for steroid-resistant systemic lupus erythematosus.

Authors:  M Hashimoto; S Nonaka; E Furuta; T Wada; Y Suenaga; M Yasuda; M Shingu; M Nobunaga
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

9.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

Authors:  B N Cronstein; D Naime; E Ostad
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

10.  The effect of methotrexate on lipoxygenase metabolism in neutrophils from rats: in vitro and ex vivo studies.

Authors:  J S Hawkes; L G Cleland; M J James
Journal:  Agents Actions       Date:  1993-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.